Interleukin-6 is a better predictor of mortality as compared to C-reactive protein, homocysteine, pentosidine and advanced oxidation protein products in hemodialysis patients

Blood Purification

Volumn 26, Issue 2, 2008, Pages 204-210

  Pachaly, Maria A ^a,b   Do Nascimento, Marcelo M ^a,b,c   Suliman, Mohamed E ^c   Hayashi, Shirley Y ^c   Riella, Miguel C ^a   Manfro, Roberto C ^b   Stenvinkel, Peter ^c   Lindholm, Bengt ^c  

^a PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Advanced oxidation protein products; C reactive protein; Hemodialysis, mortality; Homocysteine; Interleukin 6; Pentosidine

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; C REACTIVE PROTEIN; HOMOCYSTEINE; INTERLEUKIN 6; PENTOSIDINE;

ADULT; ARTICLE; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; SURVIVAL RATE;

ADULT; ARGININE; C-REACTIVE PROTEIN; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HOMOCYSTEINE; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; LYSINE; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PROGNOSIS; PROTEINS; RENAL DIALYSIS; SURVIVAL RATE;

EID: 40949123511     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000117438     Document Type: Article

References (30)

1. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61.
2. Makita S, Nakamura M, Hiramori K: The association of C-reactive protein levels with carotid intima-media complex thickness and plaque formation in the general population. Stroke 2005;36:2138-2142.
3. Wanner C, Metzger T: C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 2002;17(suppl 8):29-32; discussion 39-40.
4. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998;32:107-114.
5. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P: Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002;17:1684-1688.
6. Rao M, Guo D, Perianayagam MC, Tighiouart H, Jaber BL, Pereira BJ, Balakrishnan VS: Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2005;45:324-333.
7. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62: 1524-1538.
8. Suliman ME, Stenvinkel P, Jogestrand T, Maruyama Y, Qureshi AR, Barany P, Heimburger O, Lindholm B: Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy. Clin Nephrol 2006;66:418-425.
9. Witko-Sarsat V, Gausson V, Descamps-Latscha B: Are advanced oxidation protein products potential uremic toxins? Kidney Int 2003;84:S11-S14.
10. Suliman ME, Qureshi AR, Barany P, Stenvinkel P, Filho JC, Anderstam B, Heimburger O, Lindholm B, Bergstrom J: Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000;57:1727-1735.
11. Valli A, Suliman ME, Meert N, Vanholder R, Lindholm B, Stenvinkel P, Watanabe M, Barany P, Alvestrand A, Anderstam B: Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. Clin Chim Acta 2007;379:87-94.
12. Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, Bertini A, Sposini S, Perez-Garcia R, Rindi P, Palla R, Tetta C: Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004;19:1154-1160.
13. Tripepi G, Mallamaci F, Zoccali C: Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005;16:S83-S88.
14. Zoccali C, Tripepi G, Mallamaci F: Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J Am Soc Nephrol 2006;17: S169-S173.
15. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG: C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 2005;112: 976-983.
16. Pober JS, Cotran RS: Cytokines and endothelial cell biology. Physiol Rev 1990;70:427-451.
17. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148:209-214.
18. Turk JR, Carroll JA, Laughlin MH, Thomas TR, Casati J, Bowles DK, Sturek M: C-reactive protein correlates with macrophage accumulation in coronary arteries of hypercholesterolemic pigs. J Appl Physiol 2003;95: 1301-1304.
19. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
20. Nascimento MM, Pecoits-Filho R, Qureshi AR, Hayashi SY, Manfro RC, Pachaly MA, Renner L, Stenvinkel P, Lindholm B, Riella MC: The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. Nephrol Dial Transplant 2004;19:2803-2809.
21. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-1911.
22. Honda H, Qureshi AR, Heimburger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B: Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006;47:139-148.
23. Suliman ME, Barany P, Kalantar-Zadeh K, Lindholm B, Stenvinkel P: Homocysteine in uraemia - a puzzling and conflicting story. Nephrol Dial Transplant 2005;20:16-21.
24. Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C: Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 2005;67: 2330-2337.
25. Suliman M, Stenvinkel P, Qureshi AR, Kalantar-Zadeh K, Barany P, Heimburger O, Vonesh EF, Lindholm B: The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrol Dial Transplant 2007;22:209-217.
26. Ducloux D, Klein A, Kazory A, Devillard N, Chalopin JM: Impact of malnutrition-inflammation on the association between homocysteine and mortality. Kidney Int 2006; 69:331-335.
27. Taki K, Takayama F, Tsuruta Y, Niwa T: Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int 2006;70: 218-224.
28. Suliman ME, Heimburger O, Barany P, Anderstam B, Pecoits-Filho R, Rodriguez Ayala E, Qureshi AR, Fehrman-Ekholm I, Lindholm B, Stenvinkel P: Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 2003;14:1614-1622.
29. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, London GM, Jungers P: Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005;45:39-47.
30. Kaysen GA, Levin NW, Mitch WE, Chapman AL, Kubala L, Eiserich JP: Evidence that C-reactive protein or IL-6 are not surrogates for all inflammatory cardiovascular risk factors in hemodialysis patients. Blood Purif 2006;24:508-516.